Hanmi, promotes COVID-19 tx, Ambroxol HCl Sln for Inhalation

China approved product, recommended for COVID-19 treatment

Approval process is in progress in the US, Europe and Korea

Beijing Hanmi’s Ambroxol HCl Solution for Inhalation

Hanmi's Chinese subsidiary, Beijing Hanmi Pharmaceutical, announced on the 6th that it will develop a secretolytic agent, 'Ambroxol HCl Solution for Inhalation' as COVID-19 treatment.

 

Earlier, top expert consensus in Chinese pediatrics and two organizations at the drug management control center in Guangdong Province, China, commented on 'Ambroxol HCl Solution for Inhalation' as a recommended drug for COVID-19.

 

In China, prognosis that significantly lowers the risk of hypoxia death due to 'acute respiratory disorder symptom (ARDS)' and 'cytokine release syndrome (CRS)', an overactive immune response, has been reported in patients with COVID-19 who received 'Ambroxol HCl Solution for Inhalation' for the purpose of treating expectorant.

 

'Ambroxol HCl Solution for Inhalation' is a treatment for a secretolytic agent in the form of a vaporizer that is inhaled by mouth.

 

Since its first commercialization in Germany in 1979, it is based on 'Ambroxol', which is widely used around the world.

 

Alveolar Type II Cells secrete surfactants so that expectorants do not stick to the alveoli and are easily discharged.

 

It was approved in July of last year in China.

 

Hanmi plans to promote a clinical trial that uses the expectorant in combination with COVID-19 treatment.

 

Starting with Hyeophwa Hospital affiliated with Wuhan University of Science and Technology, which is a 5,000-bed high-level university hospital in Wuhan, China, a full-scale clinical discussion has begun with Beijing Ditan Hospital and Shanghai Public Health Clinical Center.

 

Hanmi is in the process of obtaining approval for this expectorant in the US, Europe, and Korea.

 

An official of Hanmi said, "This expectorant's clinical trial will be linked to the 'Hanmi Covid MDT Program', an innovative integrated treatment regimen of Hanmi that covers the entire COVID-19 treatment."